



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – June 8, 2016

## **NUCLEAR MEDICINE MARKET: MODEST GROWTH DURING THE LAST TWO YEARS**

MEDraysintell estimates that the global market for nuclear medicine (radiopharmaceuticals) reached US\$ 4.3 billion in 2015, growing by just over 2% a year between 2013 and 2015. This slow growth is primarily driven by lower revenues from technetium-99m related products and an unfavorable impact from US\$ exchange rates versus major currencies. This slow progression is compensated by a robust increase of the radiotherapeutics which have grown by about 60% a year from 2013 to 2015, mostly driven by one product, Xofigo from Bayer. Without this exchange rate influence, MEDraysintell estimates that the nuclear medicine market would have reached over US\$ 4.7 billion in 2015, thereby exhibiting an annual growth of more than 7% for the period 2013-2015.

While it has been stable last year, the global nuclear medicine market is expected to climb to US\$ 25 billion by 2030. Several factors indicate an increasing demand for nuclear medicine procedures, including a wider use of nuclear medicine around the world (other applications besides oncology and cardiology) and the introduction of new radiopharmaceuticals. The molybdenum-99 shortage issue which will be solved within the next two years will also influence additional growth. Yet, the most important factor that will shape the future growth of the nuclear medicine market is the launch of new generation therapeutic radiopharmaceuticals.

All these topics are extensively covered in the new Nuclear Medicine World Market Report & Directory, Edition 2016 to be published shortly after SNMMI. It is a 990–pages report & directory describing and analyzing over 360 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in nuclear medicine.

MEDraysintell will display its series of market reports and directories with over 1,800 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the SNMMI – Society of Nuclear Medicine and Molecular Imaging– congress (San Diego, CA, USA, June 11-15, 2016). <http://www.snmmi.org/am2016>

MEDraysintell is gratefully hosted by the company ANMI and visitors are welcome at booth #230.

### **About MEDraysintell**

**Strategic intelligence for the radiation healthcare**

*Bringing value to Businesses and Investors!*

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. [www.medraysintell.com](http://www.medraysintell.com)

### **Contact**

**Paul-Emmanuel Goethals, MBA**  
Louvain-la-Neuve, Belgium  
e-Mail: [peg@medraysintell.com](mailto:peg@medraysintell.com)  
Mobile: +32 491 080 968

**Richard Zimmermann, PhD**  
Lalaye, France  
e-Mail: [rz@medraysintell.com](mailto:rz@medraysintell.com)  
Mobile: +33 6 82 80 06 00